Crossmark

511 Initial results of a phase 1 study of intratumoral ONCR-177, an oncolytic herpes-simplex virus-1 expressing five immunomodulatory transgenes, in subjects with advanced injectable tumors

Crossref DOI link: https://doi.org/10.1136/jitc-2021-SITC2021.511

Published Online: 2021-11-10

Published Print: 2021-11

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Park, Jong Chul

Soliman, Hatem

Falchook, Gerald

Owonikoko, Taofeek

Spreafico, Anna

Massarelli, Erminia

McKean, Meredith

Chow, Laura

Ott, Patrick

Wesolowski, Robert

Fountzilas, Christos

Whalen, Corey

Yanez, Adrienne

Dupont, Christopher

Auer, Julia

Cheema, Tooba

Goldberg, John

Ashburn, Ted

Puzanov, Igor
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct04348916 at ClinicalTrials.gov

Documents that mention this clinical trial

511 Initial results of a phase 1 study of intratumoral ONCR-177, an oncolytic herpes-simplex virus-1 expressing five immunomodulatory transgenes, in subjects with advanced injectable tumors
https://doi.org/10.1136/jitc-2021-sitc2021.511

Document is current

Any future updates will be listed below